Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHAN W ANDERSON

Allopathic & Osteopathic Physicians Radiology Diagnostic Radiology

NPI
1235243122
CMS profile
540683
Location
BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$362,885.00

209 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $362,885.00 209

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $341,425.00 183
PFIZER INC. $12,970.00 13
MEDIVATION INC. $8,490.00 13

Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHAN W ANDERSON

NPI 1235243122 · CMS profile ID 540683

Allopathic & Osteopathic Physicians / Radiology / Diagnostic Radiology

BOSTON, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1235243122?year=2020&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHAN W ANDERSON, NPI 1235243122, CMS profile ID 540683. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1235243122?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). STEPHAN W ANDERSON, NPI 1235243122, CMS profile ID 540683. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1235243122?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
STEPHAN W ANDERSON, NPI 1235243122, CMS profile ID 540683, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 209 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1235243122?year=2020&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

209 matching records · $362,885.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 209 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 209.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme Corporation $3,055.0010/12/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747797931 CMS
Merck Sharp & Dohme Corporation $345.0010/12/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747797935 CMS
Merck Sharp & Dohme Corporation $1,080.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747842551 CMS
Merck Sharp & Dohme Corporation $120.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747842553 CMS
Merck Sharp & Dohme Corporation $125.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747842661 CMS
Merck Sharp & Dohme Corporation $1,330.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747842671 CMS
Merck Sharp & Dohme Corporation $1,800.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747842789 CMS
Merck Sharp & Dohme Corporation $250.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747842885 CMS
Merck Sharp & Dohme Corporation $60.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843251 CMS
Merck Sharp & Dohme Corporation $60.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843253 CMS
Merck Sharp & Dohme Corporation $610.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843259 CMS
Merck Sharp & Dohme Corporation $6,185.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843261 CMS
Merck Sharp & Dohme Corporation $640.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843335 CMS
Merck Sharp & Dohme Corporation $660.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747843337 CMS
Merck Sharp & Dohme Corporation $3,180.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747850281 CMS
Merck Sharp & Dohme Corporation $2,760.0010/07/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747851017 CMS
MEDIVATION INC. $500.0009/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743508165 CMS
Merck Sharp & Dohme Corporation $1,560.0009/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747776333 CMS
Merck Sharp & Dohme Corporation $255.0009/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747776505 CMS
Merck Sharp & Dohme Corporation $585.0009/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747776515 CMS
Merck Sharp & Dohme Corporation $190.0009/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747777063 CMS
PFIZER INC. $130.0009/08/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743507805 CMS
Merck Sharp & Dohme Corporation $725.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802227 CMS
Merck Sharp & Dohme Corporation $720.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802295 CMS
Merck Sharp & Dohme Corporation $960.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802379 CMS
Merck Sharp & Dohme Corporation $1,040.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803323 CMS
Merck Sharp & Dohme Corporation $1,500.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803565 CMS
Merck Sharp & Dohme Corporation $2,640.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803695 CMS
Merck Sharp & Dohme Corporation $60.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803701 CMS
Merck Sharp & Dohme Corporation $3,000.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803863 CMS
Merck Sharp & Dohme Corporation $3,120.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803867 CMS
Merck Sharp & Dohme Corporation $3,900.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747804017 CMS
Merck Sharp & Dohme Corporation $125.0008/31/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747804159 CMS
MEDIVATION INC. $400.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743507813 CMS
Merck Sharp & Dohme Corporation $1,575.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626955 CMS
Merck Sharp & Dohme Corporation $3,230.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626963 CMS
Merck Sharp & Dohme Corporation $425.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626969 CMS
Merck Sharp & Dohme Corporation $50.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626971 CMS
Merck Sharp & Dohme Corporation $600.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626977 CMS
Merck Sharp & Dohme Corporation $715.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747626981 CMS
PFIZER INC. $210.0008/10/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743507809 CMS
Merck Sharp & Dohme Corporation $1,380.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802093 CMS
Merck Sharp & Dohme Corporation $6,060.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802099 CMS
Merck Sharp & Dohme Corporation $7,920.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802233 CMS
Merck Sharp & Dohme Corporation $8,040.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747802235 CMS
Merck Sharp & Dohme Corporation $180.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803569 CMS
Merck Sharp & Dohme Corporation $2,400.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803573 CMS
Merck Sharp & Dohme Corporation $600.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803857 CMS
Merck Sharp & Dohme Corporation $240.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747803931 CMS
Merck Sharp & Dohme Corporation $600.0008/06/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747804065 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $374,205.00 165
PY2020 $362,885.00 209
PY2021 $795,975.00 325
PY2022 $5,697.50 3
PY2023 $13,532.50 9
PY2024 $12,754.75 13
PY2025 $600.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $47,431.77 32
PY2025 Principal investigator $412,591.25 96
PY2024 Recipient $18,866.72 11
PY2024 Principal investigator $391,592.72 63
PY2023 Recipient $20,407.50 5
PY2023 Principal investigator $945,924.85 37
PY2022 Recipient $5,865.00 7
PY2022 Principal investigator $573,287.63 42
PY2021 Recipient $16,170.00 9
PY2021 Principal investigator $441,140.00 37
PY2020 Principal investigator $188,185.00 17
PY2019 Principal investigator $235,479.65 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

128 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $262.50 12/19/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202 No dispute reported 06/30/2026 1246641787
Principal investigator 1 ABBVIE INC. $585.00 12/09/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202529682
Principal investigator 1 ABBVIE INC. $20,370.00 12/09/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202529684
Principal investigator 1 Boehringer Ingelheim International GmbH $1,155.00 12/05/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763653
Principal investigator 1 Hexal AG $1,092.00 12/04/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348746
Principal investigator 1 Ipsen Innovation $572.00 12/04/2025 Non-covered Recipient Entity
Boston Imaging Core Lab, Llc
A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302759
Principal investigator 1 BioNTech SE $420.00 11/14/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012561
Principal investigator 1 BioNTech SE $85.00 11/14/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012563
Principal investigator 1 BioNTech SE $85.00 11/14/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111 No dispute reported 06/30/2026 1249012579
Principal investigator 1 BioNTech SE $85.00 11/14/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111 No dispute reported 06/30/2026 1249012581
Principal investigator 1 ABBVIE INC. $480.00 11/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202523775
Principal investigator 1 ABBVIE INC. $22,710.00 11/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202523777
Principal investigator 1 Hexal AG $52.00 11/06/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348742
Principal investigator 1 Hexal AG $1,456.00 11/06/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348744
Principal investigator 1 Ipsen Innovation $572.00 11/06/2025 Non-covered Recipient Entity
Boston Imaging Core Lab, Llc
A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302757
Principal investigator 1 ABBVIE INC. $20,220.00 10/16/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202517087
Recipient GlaxoSmithKline, LLC. $5,724.09 10/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192117853
Principal investigator 1 Boehringer Ingelheim International GmbH $3,906.00 10/14/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763643
Principal investigator 1 Boehringer Ingelheim International GmbH $2,695.00 10/14/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763645
Principal investigator 1 BioNTech SE $840.00 10/09/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012553
Principal investigator 1 BioNTech SE $170.00 10/09/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012555
Principal investigator 1 BioNTech SE $1,105.00 10/09/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111 No dispute reported 06/30/2026 1249012577
Recipient Hexal AG $300.00 10/09/2025 Covered Recipient Physician CJPB898A12301 No dispute reported 06/30/2026 1186349014
Principal investigator 1 ABBVIE INC. $1,370.00 10/07/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202513377
Principal investigator 1 BioNTech SE $87.50 10/03/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012497
Principal investigator 1 BioNTech SE $1,020.00 10/03/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012543
Principal investigator 1 BioNTech SE $85.00 10/03/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT122 No dispute reported 06/30/2026 1249012545
Principal investigator 1 Hexal AG $104.00 10/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348738
Principal investigator 1 Hexal AG $2,964.00 10/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348740
Recipient Regeneron Pharmaceuticals, Inc. $447.50 10/03/2025 Covered Recipient Physician A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) + CEMIPLIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184115135
Recipient GlaxoSmithKline, LLC. $2,550.91 09/16/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192117872
Principal investigator 1 ABBVIE INC. $520.00 09/09/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202510284
Principal investigator 1 ABBVIE INC. $25,575.00 09/09/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202510286
Principal investigator 1 Hexal AG $52.00 09/04/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348734
Principal investigator 1 Hexal AG $2,236.00 09/04/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348736
Recipient GlaxoSmithKline, LLC. $460.58 08/10/2025 Covered Recipient Physician A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1192117865
Recipient GlaxoSmithKline, LLC. $1,712.72 08/10/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192121865
Principal investigator 1 Hexal AG $52.00 08/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348784
Principal investigator 1 Hexal AG $2,808.00 08/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348786
Principal investigator 1 BioNTech SE $840.00 08/07/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012671
Principal investigator 1 BioNTech SE $170.00 08/07/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012673
Recipient Hexal AG $180.00 08/07/2025 Covered Recipient Physician CJPB898A12301 No dispute reported 06/30/2026 1186348976
Principal investigator 1 Boehringer Ingelheim International GmbH $1,870.00 08/06/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763641
Principal investigator 1 ABBVIE INC. $2,220.00 08/05/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202501052
Recipient GlaxoSmithKline, LLC. $318.85 07/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192121851
Recipient GlaxoSmithKline, LLC. $1,371.37 07/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192173290
Principal investigator 1 BioNTech SE $2,340.00 07/10/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012655
Principal investigator 1 BioNTech SE $425.00 07/10/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012657
Principal investigator 1 BioNTech SE $87.50 07/10/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012659
Principal investigator 1 ABBVIE INC. $5,820.00 07/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202497164
Principal investigator 1 ABBVIE INC. $1,330.00 07/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202497190
Principal investigator 1 AstraZeneca UK Limited $7,890.00 07/08/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
a phase third,randomized,double blind,placebo controlled,multi centre,global study of volrustomig in women with high risk locally advanced cervical cancer who have not progressed following platinum based,concurrent chemoradiation therapy evolve cervical No dispute reported 06/30/2026 1185551569
Recipient GlaxoSmithKline, LLC. $480.00 07/08/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192121871
Recipient Hexal AG $300.00 07/08/2025 Covered Recipient Physician CJPB898A12301 No dispute reported 06/30/2026 1186348986
Principal investigator 1 Boehringer Ingelheim International GmbH $5,390.00 07/03/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763639
Principal investigator 1 Hexal AG $1,612.00 07/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348780
Principal investigator 1 Hexal AG $156.00 07/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348782
Principal investigator 1 BioNTech SE $1,140.00 06/19/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012639
Principal investigator 1 BioNTech SE $425.00 06/19/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012641
Principal investigator 1 BioNTech SE $340.00 06/19/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111-01 No dispute reported 06/30/2026 1249012645
Recipient GlaxoSmithKline, LLC. $2,400.00 06/19/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192173281
Recipient GlaxoSmithKline, LLC. $1,114.54 06/11/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192117885
Principal investigator 1 Hexal AG $1,092.00 06/06/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348776
Principal investigator 1 Hexal AG $52.00 06/06/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348778
Principal investigator 1 ABBVIE INC. $1,685.00 06/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202487415
Principal investigator 1 ABBVIE INC. $1,315.00 06/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202487585
Principal investigator 1 Boehringer Ingelheim International GmbH $1,925.00 05/30/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763637
Principal investigator 1 BioNTech SE $900.00 05/15/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012615
Principal investigator 1 BioNTech SE $765.00 05/15/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012617
Principal investigator 1 BioNTech SE $540.00 05/15/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012633
Principal investigator 1 BioNTech SE $340.00 05/15/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012635
Recipient Regeneron Pharmaceuticals, Inc. $60.00 05/15/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184115133
Principal investigator 1 ABBVIE INC. $1,890.00 05/13/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202484779
Principal investigator 1 AstraZeneca UK Limited $4,040.00 05/13/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185551563
Recipient GlaxoSmithKline, LLC. $1,629.45 05/13/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117858
Recipient GlaxoSmithKline, LLC. $2,092.28 05/13/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192173261
Principal investigator 1 Hexal AG $832.00 05/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348772
Principal investigator 1 Hexal AG $62.50 05/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348774
Principal investigator 1 Boehringer Ingelheim International GmbH $1,815.00 05/01/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763635
Principal investigator 1 ABBVIE INC. $810.00 04/29/2025 Non-covered Recipient Entity
MGPO RADIOLOGY ASSOCIATES
Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 1202479801
Principal investigator 1 BioNTech SE $85.00 04/26/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111-01 No dispute reported 06/30/2026 1249012595
Principal investigator 1 Boehringer Ingelheim International GmbH $1,045.00 04/17/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763633
Recipient GlaxoSmithKline, LLC. $908.50 04/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117846
Recipient GlaxoSmithKline, LLC. $2,405.29 04/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192173285
Principal investigator 1 BioNTech SE $1,445.00 04/10/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111-01 No dispute reported 06/30/2026 1249012623
Principal investigator 1 BioNTech SE $360.00 04/10/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT111-01 No dispute reported 06/30/2026 1249012625
Recipient GlaxoSmithKline, LLC. $3,322.50 04/10/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192173276
Recipient Hexal AG $330.00 04/10/2025 Covered Recipient Physician CJPB898A12301 No dispute reported 06/30/2026 1186348948
Recipient Regeneron Pharmaceuticals, Inc. $510.00 04/10/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184115131
Principal investigator 1 ABBVIE INC. $1,600.00 04/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202475029
Principal investigator 1 ABBVIE INC. $2,060.00 04/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202475033
Principal investigator 1 Novo Nordisk AS $1,995.00 04/08/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB, LLC
NN9536-4512 No dispute reported 06/30/2026 1213725487
Principal investigator 1 BioNTech SE $360.00 04/03/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012605
Principal investigator 1 BioNTech SE $340.00 04/03/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012607
Recipient GlaxoSmithKline, LLC. $2,940.00 04/03/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192173269
Principal investigator 1 Hexal AG $2,132.00 04/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348768
Principal investigator 1 Hexal AG $52.00 04/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348770
Recipient Regeneron Pharmaceuticals, Inc. $3,485.00 04/03/2025 Covered Recipient Physician A PHASE 1/2 STUDY OF REGN4018 (A MUC16XCD3 BISPECIFIC ANTIBODY) ADMINISTERED ALONE OR IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH RECURRENT OVARIAN CANCER No dispute reported 06/30/2026 1184115129
Principal investigator 1 Boehringer Ingelheim International GmbH $1,870.00 03/18/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763651
Recipient GlaxoSmithKline, LLC. $1,344.55 03/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192173265
Principal investigator 1 ABBVIE INC. $1,600.00 03/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202462260
Principal investigator 1 ABBVIE INC. $5,730.00 03/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202462615
Recipient GlaxoSmithKline, LLC. $1,340.57 03/11/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192121859
Principal investigator 1 Novo Nordisk AS $950.00 03/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB, LLC
NN9536-4512 No dispute reported 06/30/2026 1213833468
Principal investigator 1 Hexal AG $988.00 03/06/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348766
Recipient GlaxoSmithKline, LLC. $1,625.00 02/12/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117891
Principal investigator 1 ABBVIE INC. $1,410.00 02/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202450551
Recipient GlaxoSmithKline, LLC. $1,530.00 02/11/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192117898
Principal investigator 1 Novo Nordisk AS $11,970.00 02/11/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB, LLC
NN9536-4512 No dispute reported 06/30/2026 1213833028
Principal investigator 1 Boehringer Ingelheim International GmbH $1,375.00 02/10/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763649
Principal investigator 1 AstraZeneca UK Limited $34,295.00 02/06/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185551565
Principal investigator 1 BioNTech SE $600.00 02/06/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012589
Principal investigator 1 BioNTech SE $85.00 02/06/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012591
Recipient GlaxoSmithKline, LLC. $1,827.50 02/06/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192173273
Principal investigator 1 Hexal AG $520.00 02/06/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348764
Principal investigator 1 Ipsen Innovation $62.50 02/06/2025 Non-covered Recipient Entity
Boston Imaging Core Lab, Llc
A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment No dispute reported 06/30/2026 1184302755
Recipient GlaxoSmithKline, LLC. $1,004.55 01/15/2025 Covered Recipient Physician A PHASE 2, SINGLE-ARM, OPEN-LABEL STUDY WITH DOSTARLIMAB MONOTHERAPY I No dispute reported 06/30/2026 1192117832
Recipient GlaxoSmithKline, LLC. $1,408.52 01/15/2025 Covered Recipient Physician A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117840
Principal investigator 1 Amgen Inc. $40,421.25 01/14/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO (Nivolumab) in Subjects With Treatment-Nave Unresectable or Metastatic Melanoma No dispute reported 06/30/2026 1246641818
Principal investigator 1 BioNTech SE $720.00 01/09/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012583
Principal investigator 1 BioNTech SE $425.00 01/09/2025 Non-covered Recipient Entity
GI REVIEWERS LLC
BNT-122-01 No dispute reported 06/30/2026 1249012585
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $102,887.50 01/09/2025 Non-covered Recipient Entity
GI Reviewers
A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination With Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants With Advanced Hepatocellular Carcinoma No dispute reported 06/30/2026 1235997099
Recipient GlaxoSmithKline, LLC. $1,860.00 01/09/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192117879
Recipient Regeneron Pharmaceuticals, Inc. $447.50 01/09/2025 Covered Recipient Physician A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184115127
Principal investigator 1 ABBVIE INC. $1,935.00 01/07/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202437119
Principal investigator 1 AstraZeneca UK Limited $26,070.00 01/07/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation No dispute reported 06/30/2026 1185551567
Principal investigator 1 Boehringer Ingelheim International GmbH $825.00 01/03/2025 Non-covered Recipient Entity
Boston Imaging Core Lab
Beamion LUNG-2: A Phase III, open-label, randomised, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared to standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations No dispute reported 06/30/2026 1220763647
Principal investigator 1 Hexal AG $468.00 01/03/2025 Non-covered Recipient Entity
BOSTON IMAGING CORE LAB
CGME751A12301 No dispute reported 06/30/2026 1186348762